Posted by Michael Wonder on 28 Nov 2023
Autolus Therapeutics submits biologics license application to US FDA for obecabtagene autoleucel (obe-cel) for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia
27 November 2023 - BLA submission includes results from pivotal Phase 2 FELIX study evaluating obe-cel in relapsed/refractory adult B-cell acute lymphoblastic leukaemia.
Autolus Therapeutics today announces that it has submitted a biologics license application to the US FDA for obecabtagene autoleucel (obe-cel).
